Display options
Cite
Yanai A, Sakamoto K, Akanuma M, et al. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan. World J Gastrointest Pharmacol Ther. 2012;3(1):1-6doi: 10.4292/wjgpt.v3.i1.1.
Yanai, A., Sakamoto, K., Akanuma, M., Ogura, K., & Maeda, S. (2012). Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan. World journal of gastrointestinal pharmacology and therapeutics, 3(1), 1-6. https://doi.org/10.4292/wjgpt.v3.i1.1
Yanai, Ayako, et al. "Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan." World journal of gastrointestinal pharmacology and therapeutics vol. 3,1 (2012): 1-6. doi: https://doi.org/10.4292/wjgpt.v3.i1.1
Yanai A, Sakamoto K, Akanuma M, Ogura K, Maeda S. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan. World J Gastrointest Pharmacol Ther. 2012 Feb 06;3(1):1-6. doi: 10.4292/wjgpt.v3.i1.1. PMID: 22408744; PMCID: PMC3296803.
Copy Download .nbib Format: NLM
Share it on

World J Gastrointest Pharmacol Ther. 2012 Feb 06;3(1):1-6. doi: 10.4292/wjgpt.v3.i1.1.

Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan.

World journal of gastrointestinal pharmacology and therapeutics

Ayako Yanai, Kei Sakamoto, Masao Akanuma, Keiji Ogura, Shin Maeda

Affiliations

  1. Ayako Yanai, Department of Gastroenterology, Toranomon Hospital Kajigaya, 1-3-1 Kajigaya, Takatsu-ku, Kawasaki, Kanagawa 213-8587, Japan.

PMID: 22408744 PMCID: PMC3296803 DOI: 10.4292/wjgpt.v3.i1.1

Abstract

AIM: To find the way to improve the eradication rate of first-line therapy in Japanese patients.

METHODS: We prospectively compared the effectiveness of 7-d quadruple therapy to standard 7 d triple therapy in Japanese patients infected with Helicobacter pylori (H. pylori). One hundred and nineteen patients were randomly assigned to receive 7-d non-bismuth quadruple therapy with lansoprazole, amoxicillin, clarithromycin and metronidazole (LACM7) or 7-d triple therapy with lansoprazole, amoxicillin and clarithromycin (LAC7). After three months, H. pylori status was analyzed by (13)C-urea breath test. Incidence rates of adverse events were evaluated by use of questionnaires.

RESULTS: By intention-to-treat (ITT) analysis, the eradication rate in the LACM7 group was 94.9%, which was significantly higher than the LAC7 group (68.3%, P < 0.001). Per protocol analysis also showed a significantly higher eradication rate in the LACM7 group (98.3%) than the LAC7 group (73.2%, P < 0.001). Nevertheless, the incidence of serious adverse events did not differ between the two groups (RR: 1.10, 95% CI: 0.70-1.73, P = 0.67).

CONCLUSION: Seven day non-bismuth quadruple therapy (LACM7) was superior to standard 7-d triple therapy (LAC7) for first-line eradication.

Keywords: Eradication; First-line treatment; Helicobacter pylori; Non-bismuth quadruple therapy; Prospective study

References

  1. N Engl J Med. 2001 Sep 13;345(11):784-9 - PubMed
  2. Am J Gastroenterol. 1989 Aug;84(8):958-60 - PubMed
  3. Blood. 2009 Feb 5;113(6):1231-40 - PubMed
  4. Aliment Pharmacol Ther. 1999 Apr;13(4):497-501 - PubMed
  5. Cancer Res. 2003 May 15;63(10):2569-77 - PubMed
  6. Eur J Gastroenterol Hepatol. 2002 Nov;14(11):1237-43 - PubMed
  7. Arch Intern Med. 1999 Jul 26;159(14):1562-6 - PubMed
  8. Gastroenterology. 2002 Dec;123(6):1763-9 - PubMed
  9. Lancet. 2008 Aug 2;372(9636):392-7 - PubMed
  10. J Gastroenterol Hepatol. 2009 Oct;24(10):1587-600 - PubMed
  11. Gut. 2007 Jun;56(6):772-81 - PubMed
  12. Gut. 2004 Jan;53(1):34-7 - PubMed
  13. J Clin Microbiol. 2007 Dec;45(12):4006-10 - PubMed
  14. J Dig Dis. 2007 Nov;8(4):211-5 - PubMed
  15. Helicobacter. 2001 Sep;6(3):254-61 - PubMed
  16. Am J Gastroenterol. 2003 Mar;98(3):562-7 - PubMed
  17. J Gastroenterol. 2007 Jan;42 Suppl 17:3-6 - PubMed
  18. Aliment Pharmacol Ther. 2002 Jul;16(7):1261-7 - PubMed
  19. Eur J Gastroenterol Hepatol. 2000 Dec;12(12):1315-8 - PubMed
  20. Aliment Pharmacol Ther. 2011 Sep;34(6):604-17 - PubMed
  21. Mayo Clin Proc. 1988 Feb;63(2):147-53 - PubMed
  22. Eur J Clin Pharmacol. 2007 Aug;63(8):743-9 - PubMed
  23. Indian J Gastroenterol. 2003 May-Jun;22(3):85-7 - PubMed
  24. Antimicrob Agents Chemother. 2002 Jul;46(7):2244-8 - PubMed
  25. Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):639-42 - PubMed
  26. Korean J Gastroenterol. 2005 Nov;46(5):368-72 - PubMed
  27. Gut. 2006 Dec;55(12):1711-6 - PubMed

Publication Types